Lisinopril
- Generic Name
- Lisinopril
- Brand Names
- Prinivil, Qbrelis, Zestoretic, Zestril
- Drug Type
- Small Molecule
- Chemical Formula
- C21H31N3O5
- CAS Number
- 76547-98-3
- Unique Ingredient Identifier
- 7Q3P4BS2FD
- Background
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therap...
- Indication
Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.
- Associated Conditions
- Acute Myocardial Infarction (AMI), Cardiovascular Events, Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension, Migraine
- Associated Therapies
- -
OptiZ: Real World Evidence Study
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Closed Loop Medicine
- Target Recruit Count
- 113
- Registration Number
- NCT06745726
- Locations
- 🇬🇧
Oak Street Medical Practice, Norwich, United Kingdom
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- Conditions
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 716
- Registration Number
- NCT05056727
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Eastern Virginia Medical School
- Registration Number
- NCT05016440
- Locations
- 🇺🇸
Eastern Virginia Medical School, Norfolk, Virginia, United States
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT04550481
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT04190433
N-of-1 Trials In Children With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2022-09-09
- Target Recruit Count
- 49
- Registration Number
- NCT03461003
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 75
- Registration Number
- NCT03422705
Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.
- Conditions
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Ascension Health
- Registration Number
- NCT03392740
- Locations
- 🇺🇸
Genesys Regional Medical Center, Grand Blanc, Michigan, United States
Optimal Management of HIV Infected Adults At Risk for Kidney Complications in Nigeria
- Conditions
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 280
- Registration Number
- NCT03201939
- Locations
- 🇳🇬
Aminu Kano Teaching Hospital, Kano, Nigeria
Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Hospital General Universitario Gregorio Marañon
- Target Recruit Count
- 106
- Registration Number
- NCT03195023
- Locations
- 🇪🇸
Gregorio Maranon Hospital, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.